title: Turkey herpesvirus with an insertion in the UL3-4 region displays an appropriate balance between growth activity and antibody-eliciting capacity and is suitable for the establishment of a recombinant vaccine.
abstract: We constructed turkey herpesvirus (HVT) vector vaccines in which the VP2 gene of infectious bursal disease virus (IBDV) was inserted into the HVT genome in the following regions: UL3-4, UL22-23, UL45-46, and US10-SORF3. We then evaluated the relationship between the gene insertion site and the capacity of the virus to elicit antibodies. rHVT/IBD (US10) showed good growth activity in vitro, with growth comparable to that of the parent HVT. On the other hand, rHVT/IBD (UL3-4), rHVT/IBD (UL22-23), and rHVT/IBD (UL45-46) exhibited decreased growth activity in chicken embryo fibroblast (CEF) cells compared to the parent HVT. However, the rHVT/IBD (US10) elicited lower levels of virus-neutralizing (VN) antibodies compared to the other constructs. rHVT/IBD (UL3-4) and rHVT/IBD (UL45-46) appeared to be similar in their ability to elicit VN antibodies. Based on the results of in vitro and in vivo assays, rHVT/IBD (UL3-4) was selected for further testing. In a challenge assay, rHVT/IBD (UL3-4) protected chickens from challenge with virulent Marek's disease virus serotype 1 and IBDV. In conclusion, the site of gene insertion may have a strong effect on the growth of the vector virus in vitro and its antibody-eliciting capacity. Insertions in the UL3-4 region permitted a balance between growth activity and VN-antibody-eliciting capacity, and this region might therefore be an appropriate insertion site for IBDV VP2.
authors.affiliation: Animal Pharmaceuticals Division, The Chemo-Sero-Therapeutic Research Institute, 1-6-1 Okubo, Kita-ku, Kumamoto, Kumamoto, 860-8568, Japan. andou-ki@kaketsuken.or.jp.
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Andoh
authors.affiliation: Animal Pharmaceuticals Division, The Chemo-Sero-Therapeutic Research Institute, 1-6-1 Okubo, Kita-ku, Kumamoto, Kumamoto, 860-8568, Japan.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Yamazaki
authors.affiliation: Animal Pharmaceuticals Division, The Chemo-Sero-Therapeutic Research Institute, 1-6-1 Okubo, Kita-ku, Kumamoto, Kumamoto, 860-8568, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Honda
authors.affiliation: Animal Pharmaceuticals Division, The Chemo-Sero-Therapeutic Research Institute, 1-6-1 Okubo, Kita-ku, Kumamoto, Kumamoto, 860-8568, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Honda
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology*; D002645:Chickens; D026002:Herpesvirus 1, Meleagrid / Q000737:chemistry / Q000235:genetics / Q000254:growth & development / Q000276:immunology*; D008381:Herpesvirus 2, Gallid / Q000276:immunology / Q000502:physiology; D008380:Marek Disease / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D016254:Mutagenesis, Insertional; D011201:Poultry Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D014422:Turkeys; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000235:genetics / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D014614:Vaccines, Synthetic; D014764:Viral Proteins; D014765:Viral Vaccines